Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2337/dbi16-0069 http://scihub22266oqcxt.onion/10.2337/dbi16-0069 C5482091!5482091 !28603140     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28603140 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28603140 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Diabetes 2017 ; 66 (7 ): 1770-1778 Nephropedia Template TP {{tp|p=28603140 |t=2017. Mining the Genome for Therapeutic Targets |pdf=|usr=}}{{28603140 }} gab.com Text Mining the Genome for Therapeutic Targets JO: Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=28603140 #FOAvip Current pharmacological options for type 2 diabetes do not cure the disease. Despite the availability of multiple drug classes that modulate glycemia effectively and minimize long-term complications, these agents do not reverse pathogenesis, and in practice they are not selected to correct the molecular profile specific to the patient. Pharmaceutical companies find drug development programs increasingly costly and burdensome, and many promising compounds fail before launch to market. Human genetics can help advance the therapeutic enterprise. Genomic discovery that is agnostic to preexisting knowledge has uncovered dozens of loci that influence glycemic dysregulation. Physiological investigation has begun to define disease subtypes, clarifying heterogeneity and suggesting molecular pathways for intervention. Convincing genetic associations have paved the way for the identification of effector transcripts that underlie the phenotype, and genetic or experimental proof of gain or loss of function in select cases has clarified the direction of effect to guide therapeutic development. Genetic studies can also examine off-target effects and furnish causal inference. As this information is curated and made widely available to all stakeholders, it is hoped that it will enhance therapeutic development pipelines by accelerating efficiency, maximizing cost-effectiveness, and raising ultimate success rates. Twit Text FOAVip Mining the Genome for Therapeutic Targets ????Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=28603140 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28603140 #FOAvip English Wikipedia <ref>{{Cite pmid|28603140 }}</ref> Mining the Genome for Therapeutic Targets #MMPMID28603140 Florez JC Diabetes 2017[Jul]; 66 (7 ): 1770-1778 PMID28603140 show ga Current pharmacological options for type 2 diabetes do not cure the disease. Despite the availability of multiple drug classes that modulate glycemia effectively and minimize long-term complications, these agents do not reverse pathogenesis, and in practice they are not selected to correct the molecular profile specific to the patient. Pharmaceutical companies find drug development programs increasingly costly and burdensome, and many promising compounds fail before launch to market. Human genetics can help advance the therapeutic enterprise. Genomic discovery that is agnostic to preexisting knowledge has uncovered dozens of loci that influence glycemic dysregulation. Physiological investigation has begun to define disease subtypes, clarifying heterogeneity and suggesting molecular pathways for intervention. Convincing genetic associations have paved the way for the identification of effector transcripts that underlie the phenotype, and genetic or experimental proof of gain or loss of function in select cases has clarified the direction of effect to guide therapeutic development. Genetic studies can also examine off-target effects and furnish causal inference. As this information is curated and made widely available to all stakeholders, it is hoped that it will enhance therapeutic development pipelines by accelerating efficiency, maximizing cost-effectiveness, and raising ultimate success rates. |*Genomics [MESH] |*Molecular Targeted Therapy [MESH] |Blood Glucose/metabolism [MESH] |Causality [MESH] |Diabetes Mellitus, Type 2/classification/*drug therapy/genetics/metabolism [MESH] |Drug Discovery/economics [MESH] |Genome-Wide Association Study [MESH] |Humans [MESH]Mining the Genome for Therapeutic Targets (epmc).pdf DeepDyve Pubget Overpricing